Literature DB >> 12885889

Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Heribert Warzecha1, Hugh S Mason, Christopher Lane, Anders Tryggvesson, Edward Rybicki, Anna-Lise Williamson, John D Clements, Robert C Rose.   

Abstract

Human papillomavirus-like particles (HPV VLPs) have shown considerable promise as a parenteral vaccine for the prevention of cervical cancer and its precursor lesions. Parenteral vaccines are expensive to produce and deliver, however, and therefore are not optimal for use in resource-poor settings, where most cervical HPV disease occurs. Transgenic plants expressing recombinant vaccine immunogens offer an attractive and potentially inexpensive alternative to vaccination by injection. For example, edible plants can be grown locally and can be distributed easily without special training or equipment. To assess the feasibility of an HPV VLP-based edible vaccine, in this study we synthesized a plant codon-optimized version of the HPV type 11 (HPV11) L1 major capsid protein coding sequence and introduced it into tobacco and potato. We show that full-length L1 protein is expressed and localized in plant cell nuclei and that expression of L1 in plants is enhanced by removal of the carboxy-terminal nuclear localization signal sequence. We also show that plant-expressed L1 self-assembles into VLPs with immunological properties comparable to those of native HPV virions. Importantly, ingestion of transgenic L1 potato was associated with activation of an anti-VLP immune response in mice that was qualitatively similar to that induced by VLP parenteral administration, and this response was enhanced significantly by subsequent oral boosting with purified insect cell-derived VLPs. Thus, papillomavirus L1 protein can be expressed in transgenic plants to form immunologically functional VLPs, and ingestion of such material can activate potentially protective humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885889      PMCID: PMC167207          DOI: 10.1128/jvi.77.16.8702-8711.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers.

Authors:  E Merle; R C Rose; L LeRoux; J Moroianu
Journal:  J Cell Biochem       Date:  1999-09-15       Impact factor: 4.429

Review 2.  Papillomavirus-like particle vaccines.

Authors:  J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst Monogr       Date:  2001

3.  Immunological analyses of human papillomavirus capsids.

Authors:  T Giroglou; M Sapp; C Lane; C Fligge; N D Christensen; R E Streeck; R C Rose
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

4.  Optimizing the biolistic process for different biological applications.

Authors:  J C Sanford; F D Smith; J A Russell
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

5.  Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region.

Authors:  D G Strike; W Bonnez; R C Rose; R C Reichman
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

6.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

9.  Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Authors:  S Gerber; C Lane; D M Brown; E Lord; M DiLorenzo; J D Clements; E Rybicki; A L Williamson; R C Rose
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene.

Authors:  H S Mason; T A Haq; J D Clements; C J Arntzen
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

View more
  34 in total

1.  Study of immunogenic properties of the candidate edible vaccine against human immunodeficiency and hepatitis B viruses based on transgenic tomato fruits.

Authors:  S N Shchelkunov; R K Salyaev; N I Rekoslavskaya; S G Pozdnyakov; A E Nesterov; V M Sumtsova; N V Pakova; U O Mishutina; T V Kopytina; R Hammond
Journal:  Dokl Biochem Biophys       Date:  2005 Mar-Apr       Impact factor: 0.788

Review 2.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

3.  Amplicon-plus targeting technology (APTT) for rapid production of a highly unstable vaccine protein in tobacco plants.

Authors:  Kasi Azhakanandam; Sandra M Weissinger; Jennifer S Nicholson; Rongda Qu; Arthur K Weissinger
Journal:  Plant Mol Biol       Date:  2007-01-14       Impact factor: 4.076

Review 4.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

5.  Social values and scientific evidence: the case of the HPV vaccines.

Authors:  Kristen Intemann; Inmaculada de Melo-Martín
Journal:  Biol Philos       Date:  2010-01-06       Impact factor: 1.461

6.  Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study.

Authors:  T Kohl; I I Hitzeroth; D Stewart; A Varsani; V A Govan; N D Christensen; A-L Williamson; E P Rybicki
Journal:  Clin Vaccine Immunol       Date:  2006-08

7.  A Virus-based Vaccine May Prevent Cervical Cancer.

Authors:  Patti E Gravitt; Keerti V Shah
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

8.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

Review 9.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

Review 10.  Plant-based oral vaccines: results of human trials.

Authors:  C O Tacket
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.